EADO 2022 | Adjuvant and neoadjuvant clinical trials for melanoma

Eva Muñoz Couselo, MD, PhD, Vall d’Hebrón Hospital, Barcelona, Spain, discusses adjuvant and neoadjuvant clinical trials for melanoma which have demonstrated a higher risk of relapse for patients with stage 2b and 3b disease than patients with 2a and 3a, as well as the relation of pathological complete response (pCR) to overall-survival (OS) for patients receiving immunotherapy. Future clinical trials will help to decipher optimal treatment strategies for patients with both non-metastatic and metastatic melanoma. This interview took place at the EADO 2022 congress.